Revisions of Consolidated Financial Forecasts
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and Representative Director: Gyo Sagara;) today announced that it has revised its consolidated financial forecasts for the full-year period ending March 2022 disclosed at the announcement of financial results ended March 2021, made on May 11, 2021, as follows:
Revisions to the Full-Year Consolidated Financial Forecasts Ending March 2022
(April 1, 2021 - March 31, 2022)
(Millions of yen, except Basic earnings per share)
Revenue Operating profit Profit before tax Profit for the year Profit for the year attributable to owners of the Company Basic earnings per share
Previous Forecast (A) 350,000 105,000 107,000 83,100 83,000 166.29 Revised Forecast (B) 345,000 103,000 105,000 81,600 81,500 163.28 Change (B – A) △5,000 △2,000 △2,000 △1,500 △1,500 - Change (%) △1.4％ △1.9％ △1.9％ △1.8％ △1.8％ - (Reference)
Results of the previous period
309,284 98,330 100,890 75,497 75,425 151.11
Reasons for Revisions
Taking into account the drug price recalculation of "Opdivo Intravenous Infusion", starting from August this year, decided at the Central Social Insurance Medical Council held on May 12, 2021, we have revised its revenue forecast downward from ¥120 billion to ¥110 billion. On the other hand, the revenue forecast for major products including new products other than "Opdivo Intravenous Infusion" has been revised upward. Consequently, we anticipate a decrease of ¥5 billion from the previously announced forecast to ¥345 billion.
Cost of sales is forecast to decrease by ¥1 billion from the previously announced forecast to ¥95 billion due to a decrease in revenue.
Selling, general and administrative expenses are expected to be ¥74 billion, a decrease of ¥2 billion from the previously announced forecast.
As a result of the above, operating profit is forecast to be ¥103 billion (decrease by ¥2 billion from the previous forecast), profit before tax ¥105 billion (decrease by 2 billion), profit for the year ¥81.6 billion (decrease by ¥1.5 billion), and profit attributable to owners of the Company ¥81.5 billion (decrease by ¥1.5 billion).
(Note) The above financial forecasts and statements contained in this announcement are made based on information available as of the announcement date. Actual results may differ materially from those set forth in the announcements due to various uncertain factors.